nach oben

Journal of Genetic Counseling

Erschienen in:

01.08.2014 | Next Generation Genetic Counseling

Cancer Risk Assessment Using Genetic Panel Testing: Considerations for Clinical Application

verfasst von: Susan Hiraki, Erica S. Rinella, Freya Schnabel, Ruth Oratz, Harry Ostrer

Erschienen in: Journal of Genetic Counseling | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

With the completion of the Human Genome Project and the development of high throughput technologies, such as next-generation sequencing, the use of multiplex genetic testing, in which multiple genes are sequenced simultaneously to test for one or more conditions, is growing rapidly. Reflecting underlying heterogeneity where a broad range of genes confer risks for one or more cancers, the development of genetic cancer panels to assess these risks represents just one example of how multiplex testing is being applied clinically. There are a number of issues and challenges to consider when conducting genetic testing for cancer risk assessment, and these issues become exceedingly more complex when moving from the traditional single-gene approach to panel testing. Here, we address the practical considerations for clinical use of panel testing for breast, ovarian, and colon cancers, including the benefits, limitations and challenges, genetic counseling issues, and management guidelines.

Akushevich, I., Kravchenko, J., Akushevich, L., Ukraintseva, S., Arbeev, K., & Yashin, A. (2011). Cancer risk and behavioral factors, comorbidities, and functional status in the US elderly population. ISRN Oncology, 2011, 1–9. doi:https://doi.org/10.5402/2011/415790.CrossRef

American Cancer Society recommendations for colorectal cancer early detection. (n.d.). Retrieved April 3, 2013, from https://doi.org/www.cancer.org/cancer/colonandrectumcancer/moreinformation/colonandrectumcancerearlydetection/colorectal-cancer-early-detection-acs-recommendations

American Cancer Society recommendations for early breast cancer detection in women without breast symptoms. (n.d.). Retrieved April 3, 2013, from https://doi.org/www.cancer.org/cancer/breastcancer/moreinformation/breastcancerearlydetection/breast-cancer-early-detection-acs-recs

Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., et al. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. American journal of human genetics, 72(5), 1117–1130. doi:https://doi.org/10.1086/375033.PubMedPubMedCentralCrossRef

Ataxia-Telangiectasia - GeneReviews^™ - NCBI Bookshelf. (n.d.). Retrieved April 8, 2013, from https://doi.org/www.ncbi.nlm.nih.gov/books/NBK26468/

Balmana, J., Castells, A., Cervantes, A., & On behalf of the ESMO Guidelines Working Group. (2010). Familial colorectal cancer risk: ESMO clinical practice guidelines. Annals of Oncology, 21(Supplement 5), v78–v81. doi:https://doi.org/10.1093/annonc/mdq169.PubMedCrossRef

Barrow, E., Robinson, L., Alduaij, W., Shenton, A., Clancy, T., Lalloo, F., et al. (2009). Cumulative lifetime incidence of extracolonic cancers in lynch syndrome: a report of 121 families with proven mutations. Clinical Genetics, 75(2), 141–149. doi:https://doi.org/10.1111/j.1399-0004.2008.01125.x.PubMedCrossRef

Berg, J. S., Khoury, M. J., & Evans, J. P. (2011). Deploying whole genome sequencing in clinical practice and public health: meeting the challenge one bin at a time. Genetics in Medicine, 13(6), 499–504. doi:https://doi.org/10.1097/GIM.0b013e318220aaba.PubMedCrossRef

Berliner, J. L., Fay, A. M., Cummings, S. A., Burnett, B., & Tillmanns, T. (2013). NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. Journal of Genetic Counseling, 22(2), 155–163. doi:https://doi.org/10.1007/s10897-012-9547-1.PubMedCrossRef

Bernstein, J. L., Haile, R. W., Stovall, M., Boice, J. D., Shore, R. E., Langholz, B., et al. (2010). Radiation exposure, the ATM gene, and contralateral breast cancer in the Women’s environmental cancer and radiation epidemiology study. JNCI Journal of the National Cancer Institute, 102(7), 475–483. doi:https://doi.org/10.1093/jnci/djq055.PubMedPubMedCentralCrossRef

Birch, J. M., Blair, V., Kelsey, A. M., Evans, D. G., Harris, M., Tricker, K. J., et al. (1998). Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene, 17(9), 1061–1068. doi:https://doi.org/10.1038/sj.onc.1202033.PubMedCrossRef

Bisgaard, M. L., Fenger, K., Bülow, S., Niebuhr, E., & Mohr, J. (1994). Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Human Mutation, 3(2), 121–125. doi:https://doi.org/10.1002/humu.1380030206.PubMedCrossRef

Boardman, L. A., Thibodeau, S. N., Schaid, D. J., Lindor, N. M., McDonnell, S. K., Burgart, L. J., et al. (1998). Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Annals of Internal Medicine, 128(11), 896–899.PubMedCrossRef

Bogdanova, N., Feshchenko, S., Schürmann, P., Waltes, R., Wieland, B., Hillemanns, P., et al. (2008). Nijmegen breakage syndrome mutations and risk of breast cancer. International Journal of Cancer, 122(4), 802–806. doi:https://doi.org/10.1002/ijc.23168.PubMedCrossRef

Bonadona, V., Bonaïti, B., Olschwang, S., Grandjouan, S., Huiart, L., Longy, M., et al. (2011). Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in lynch syndrome. JAMA: The Journal of the American Medical Association, 305(22), 2304–2310. doi:https://doi.org/10.1001/jama.2011.743.PubMedCrossRef

BreastNext | Ambry Genetics. (n.d.). Retrieved October 11, 2013, from https://doi.org/www.ambrygen.com/tests/breastnext

Brosens, L. A. A., van Hattem, A., Hylind, L. M., Iacobuzio-Donahue, C., Romans, K. E., Axilbund, J., et al. (2007). Risk of colorectal cancer in juvenile polyposis. Gut, 56(7), 965–967. doi:https://doi.org/10.1136/gut.2006.116913.PubMedPubMedCentralCrossRef

Brownstein, M. H., Wolf, M., & Bikowski, J. B. (1978). Cowden’s disease: a cutaneous marker of breast cancer. Cancer, 41(6), 2393–2398.PubMedCrossRef

Burt, R. (2007). Inheritance of colorectal cancer. Drug Discovery Today: Disease Mechanisms, 4(4), 293–300. doi:https://doi.org/10.1016/j.ddmec.2008.05.004.PubMedCrossRef

Burt, R. W., Bishop, D. T., Lynch, H. T., Rozen, P., & Winawer, S. J. (1990). Risk and surveillance of individuals with heritable factors for colorectal cancer. WHO Collaborating Centre for the Prevention of Colorectal Cancer. Bulletin of the World Health Organization, 68(5), 655–665.PubMedPubMedCentral

Byrnes, G. B., Southey, M. C., & Hopper, J. L. (2008). Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories? Breast Cancer Research: BCR, 10(3), 208. doi:https://doi.org/10.1186/bcr2099.PubMedCrossRefPubMedCentral

Casadei, S., Norquist, B. M., Walsh, T., Stray, S., Mandell, J. B., Lee, M. K., et al. (2011). Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Research, 71(6), 2222–2229. doi:https://doi.org/10.1158/0008-5472.CAN-10-3958.PubMedPubMedCentralCrossRef

Chao, S., Roberts, J. S., Marteau, T. M., Silliman, R., Cupples, L. A., & Green, R. C. (2008). Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL study. Alzheimer Disease and Associated Disorders, 22(1), 94–97. doi:https://doi.org/10.1097/WAD.0b013e31815a9dcc.PubMedPubMedCentralCrossRef

Chlebowski, R. T. (2002). Weight loss in breast cancer patient management. Journal of Clinical Oncology, 20(4), 1128–1143. doi:https://doi.org/10.1200/JCO.20.4.1128.PubMedCrossRef

Cho, M. K., Sankar, P., Wolpe, P. R., & Godmilow, L. (1999). Commercialization ofBRCA1/2 testing: practitioner awareness and use of a new genetic test. American Journal of Medical Genetics, 83(3), 157–163. doi:https://doi.org/10.1002/(SICI)1096-8628(19990319)83:3<157::AID-AJMG4>3.0.CO;2-G.PubMedPubMedCentralCrossRef

Chompret, A., Brugières, L., Ronsin, M., Gardes, M., Dessarps-Freichey, F., Abel, A., et al. (2000). P53 germline mutations in childhood cancers and cancer risk for carrier individuals. British Journal of Cancer, 82(12), 1932–1937. doi:https://doi.org/10.1054/bjoc.2000.1167.PubMedPubMedCentralCrossRef

Collins, V., Halliday, J., Kahler, S., & Williamson, R. (2001). Parents’ Experiences with genetic counseling after the birth of a baby with a genetic disorder: an exploratory study. Journal of Genetic Counseling, 10(1), 53–72.CrossRef

ColoNext | Ambry Genetics. (n.d.). Retrieved October 11, 2013, from https://doi.org/www.ambrygen.com/tests/colonext

Common Cancer Types - National Cancer Institute. (n.d.). Retrieved October 11, 2013, from https://doi.org/www.cancer.gov/cancertopics/types/commoncancers#1

Comprehensive Cancer Panel - Genetic Testing Company | The DNA Diagnostic Experts | GeneDx. (n.d.). Retrieved September 27, 2013, from https://doi.org/www.genedx.com/test-catalog/available-tests/comprehensive-cancer-panel/

Couch, F. J., DeShano, M. L., Blackwood, M. A., Calzone, K., Stopfer, J., Campeau, L., et al. (1997). BRCA1 Mutations in women attending clinics that evaluate the risk of breast cancer. The New England Journal of Medicine, 336(20), 1409–1415. doi:https://doi.org/10.1056/NEJM199705153362002.PubMedCrossRef

Cybulski, C., Wokolorczyk, D., Jakubowska, A., Huzarski, T., Byrski, T., Gronwald, J., et al. (2011). Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. Journal of Clinical Oncology, 29(28), 3747–3752. doi:https://doi.org/10.1200/JCO.2010.34.0778.PubMedCrossRef

Desjardins, S., Joly Beauparlant, C., Labrie, Y., Ouellette, G., BRCAs, I., & Durocher, F. (2009). Variations in the NBN/NBS1 gene and the risk of breast cancer in non-BRCA1/2 French Canadian families with high risk of breast cancer. BMC Cancer, 9(1), 181. doi:https://doi.org/10.1186/1471-2407-9-181.PubMedPubMedCentralCrossRef

Domchek, S. M., Bradbury, A., Garber, J. E., Offit, K., & Robson, M. E. (2013). Multiplex genetic testing for cancer susceptibility: Out on the high wire without a Net? Journal of Clinical Oncology, 31(10), 1267–1270. doi:https://doi.org/10.1200/JCO.2012.46.9403.PubMedCrossRef

Donnelly, L. S., Watson, M., Moynihan, C., Bancroft, E., Evans, D. G. R., Eeles, R., et al. (2013). Reproductive decision-making in young female carriers of a BRCA mutation. Human Reproduction (Oxford, England), 28(4), 1006–1012. doi:https://doi.org/10.1093/humrep/des441.CrossRef

Elias, S., & Annas, G. J. (1994). Generic consent for genetic screening. The New England Journal of Medicine, 330(22), 1611–1613. doi:https://doi.org/10.1056/NEJM199406023302213.PubMedCrossRef

Fletcher, O., Easton, D., Anderson, K., Gilham, C., Jay, M., & Peto, J. (2004). Lifetime risks of common cancers among retinoblastoma survivors. JNCI Journal of the National Cancer Institute, 96(5), 357–363. doi:https://doi.org/10.1093/jnci/djh058.PubMedCrossRef

Ford, D., Easton, D. F., Bishop, D. T., Narod, S. A., & Goldgar, D. E. (1994). Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet, 343(8899), 692–695.CrossRefPubMed

Frank, T. S., Manley, S. A., Olopade, O. I., Cummings, S., Garber, J. E., Bernhardt, B., et al. (1998). Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 16(7), 2417–2425.CrossRef

Gail, M. H. (2011). Personalized estimates of breast cancer risk in clinical practice and public health. Statistics in Medicine, 30(10), 1090–1104. doi:https://doi.org/10.1002/sim.4187.PubMedPubMedCentralCrossRef

genetics/BROCA - Lab Med Test Info. (n.d.). Retrieved February 4, 2013, from https://doi.org/web.labmed.washington.edu/tests/genetics/BROCA

Getting personal. (2008). Nature, 455(7216), 1007. doi:https://doi.org/10.1038/4551007a.

Gilpin, C. A., Carson, N., & Hunter, A. G. (2000). A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center. Clinical Genetics, 58(4), 299–308.PubMedCrossRef

Goldgar, D. E., Easton, D. F., Byrnes, G. B., Spurdle, A. B., Iversen, E. S., & Greenblatt, M. S. (2008). Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. Human Mutation, 29(11), 1265–1272. doi:https://doi.org/10.1002/humu.20897.PubMedPubMedCentralCrossRef

Gooding, H. C., Linnenbringer, E. L., Burack, J., Roberts, J. S., Green, R. C., & Biesecker, B. B. (2006). Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk. Patient Education and Counseling, 64(1–3), 259–267. doi:https://doi.org/10.1016/j.pec.2006.03.002.PubMedCrossRef

Green, R. C., Roberts, J. S., Cupples, L. A., Relkin, N. R., Whitehouse, P. J., Brown, T., et al. (2009). Disclosure of APOE genotype for risk of Alzheimer’s disease. The New England Journal of Medicine, 361(3), 245–254. doi:https://doi.org/10.1056/NEJMoa0809578.PubMedPubMedCentralCrossRef

Guilford, P., Humar, B., & Blair, V. (2010). Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 13(1), 1–10. doi:https://doi.org/10.1007/s10120-009-0531-x.CrossRef

Hearle, N., Schumacher, V., Menko, F. H., Olschwang, S., Boardman, L. A., Gille, J. J. P., et al. (2006). Frequency and spectrum of cancers in the peutz-jeghers syndrome. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 12(10), 3209–3215. doi:https://doi.org/10.1158/1078-0432.CCR-06-0083.CrossRef

Heikkinen, K. (2005). RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis, 27(8), 1593–1599. doi:https://doi.org/10.1093/carcin/bgi360.CrossRef

Heymann, S., Delaloge, S., Rahal, A., Caron, O., Frebourg, T., Barreau, L., et al. (2010). Radio-induced malignancies after breast cancer post-operative radiotherapy in patients with Li- fraumeni syndrome. Radiation Oncology, 5(1), 104. doi:https://doi.org/10.1186/1748-717X-5-104.PubMedCrossRefPubMedCentral

Hopper, J. L., Southey, M. C., Dite, G. S., Jolley, D. J., Giles, G. G., McCredie, M. R., et al. (1999). Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian breast cancer family study. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 8(9), 741–747.

Howe, J. R., Roth, S., Ringold, J. C., Summers, R. W., Järvinen, H. J., Sistonen, P., et al. (1998). Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science (New York, N.Y.), 280(5366), 1086–1088.CrossRef

Howe, J. R., Sayed, M. G., Ahmed, A. F., Ringold, J., Larsen-Haidle, J., Merg, A., et al. (2004). The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. Journal of Medical Genetics, 41(7), 484–491.PubMedPubMedCentralCrossRef

Hsu, H.-M., Wang, H.–. C., Chen, S.-T., Hsu, G.–. C., Shen, C.-Y., & Yu, J.–. C. (2007). Breast Cancer Risk Is Associated with the Genes Encoding the DNA Double-Strand Break Repair Mre11/Rad50/Nbs1 Complex. Cancer Epidemiology Biomarkers & Prevention, 16(10), 2024–2032. doi:https://doi.org/10.1158/1055-9965.EPI-07-0116.CrossRef

Hurley, A. C., Harvey, F. R., Roberts, J. S., Wilson-Chase, C., Lloyd, S., Prest, J., et al. (2005). Genetic susceptibility for Alzheimer’s disease: why did adult offspring seek testing? American Journal of Alzheimer's Disease and Other Dementias, 20(6), 374–381.PubMedCrossRef

Julian-Reynier, C. M., Bouchard, L. J., Evans, D. G., Eisinger, F. A., Foulkes, W. D., Kerr, B., et al. (2001). Women’s attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another. Cancer, 92(4), 959–968. doi:https://doi.org/10.1002/1097-0142(20010815)92:4<959::AID-CNCR1406>3.0.CO;2-V.PubMedCrossRef

Kempers, M. J. E., Kuiper, R. P., Ockeloen, C. W., Chappuis, P. O., Hutter, P., Rahner, N., et al. (2011). Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. The Lancet Oncology, 12(1), 49–55. doi:https://doi.org/10.1016/S1470-2045(10)70265-5.PubMedCrossRef

Khoury, M. J., Gwinn, M., Yoon, P. W., Dowling, N., Moore, C. A., & Bradley, L. (2007). The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genetics in Medicine, 9(10), 665–674. doi:https://doi.org/10.1097/GIM.0b013e31815699d0 PubMedCrossRef

Khoury, M. J., Clauser, S. B., Freedman, A. N., Gillanders, E. M., Glasgow, R. E., Klein, W. M. P., et al. (2011). Population Sciences, Translational Research, and the Opportunities and Challenges for Genomics to Reduce the Burden of Cancer in the 21st Century. Cancer Epidemiology, Biomarkers & Prevention, 20(10), 2105–2114. doi:https://doi.org/10.1158/1055-9965.EPI-11-0481.CrossRef

King, M.–. C., Marks, J. H., Mandell, J. B., & New York Breast Cancer Study Group. (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science (New York, N.Y.), 302(5645), 643–646. doi:https://doi.org/10.1126/science.1088759.CrossRef

Lalloo, F., & Evans, D. G. (2012). Familial Breast Cancer. Clinical Genetics, 82(2), 105–114. doi:https://doi.org/10.1111/j.1399-0004.2012.01859.x.PubMedCrossRef

Lerman, C., & Croyle, R. (1994). Psychological issues in genetic testing for breast cancer susceptibility. Archives of Internal Medicine, 154(6), 609–616.PubMedCrossRef

Li-Fraumeni Syndrome - GeneReviews^™ - NCBI Bookshelf. (n.d.). Retrieved April 8, 2013, from https://doi.org/www.ncbi.nlm.nih.gov/books/NBK1311/

Ligtenberg, M. J. L., Kuiper, R. P., Geurts van Kessel, A., & Hoogerbrugge, N. (2012). EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients. Familial Cancer. doi:https://doi.org/10.1007/s10689-012-9591-x.CrossRef

Marees, T., Moll, A. C., Imhof, S. M., de Boer, M. R., Ringens, P. J., & van Leeuwen, F. E. (2008). Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. Journal of the National Cancer Institute, 100(24), 1771–1779. doi:https://doi.org/10.1093/jnci/djn394.PubMedCrossRef

Martin, S. A., Lord, C. J., & Ashworth, A. (2010). Therapeutic targeting of the DNA mismatch repair pathway. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 16(21), 5107–5113. doi:https://doi.org/10.1158/1078-0432.CCR-10-0821.CrossRef

Masciari, S., Dillon, D. A., Rath, M., Robson, M., Weitzel, J. N., Balmana, J., et al. (2012). Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Research and Treatment, 133(3), 1125–1130. doi:https://doi.org/10.1007/s10549-012-1993-9.PubMedPubMedCentralCrossRef

McBride, C. M., Lipkus, I. M., Jolly, D., & Lyna, P. (2005). Interest in testing for genetic susceptibility to lung cancer among Black college students “at risk” of becoming cigarette smokers. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 14(12), 2978–2981. doi:https://doi.org/10.1158/1055-9965.EPI-05-0269.CrossRef

Mealiffe, M. E., Stokowski, R. P., Rhees, B. K., Prentice, R. L., Pettinger, M., & Hinds, D. A. (2010). Assessment of Clinical Validity of a Breast Cancer Risk Model Combining Genetic and Clinical Information. JNCI Journal of the National Cancer Institute, 102(21), 1618–1627. doi:https://doi.org/10.1093/jnci/djq388.PubMedPubMedCentralCrossRef

Meijers-Heijboer, H., van den Ouweland, A., Klijn, J., Wasielewski, M., de Snoo, A., Oldenburg, R., et al. (2002). Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nature Genetics, 31(1), 55–59. doi:https://doi.org/10.1038/ng879.PubMedCrossRef

Meiser, B., Butow, P., Friedlander, M., Schnieden, V., Gattas, M., Kirk, J., et al. (2000). Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 18(11), 2250–2257.CrossRef

Meldrum, C., Doyle, M. A., & Tothill, R. W. (2011). Next-generation sequencing for cancer diagnostics: a practical perspective. The Clinical Biochemist Reviews/Australian Association of Clinical Biochemists, 32(4), 177–195.

Multiplex genetic testing. The Council on Ethical and Judicial Affairs, American Medical Association. (1998). The Hastings Center Report, 28(4), 15–21.CrossRef

Narod, S. A. (2010). Testing for CHEK2 in the cancer genetics clinic: ready for prime time? Clinical Genetics, 78(1), 1–7. doi:https://doi.org/10.1111/j.1399-0004.2010.01402.x.PubMedCrossRef

Narod, S. A., Moody, J. R. K., Rosen, B., Fan, I., Risch, A., Sun, P., et al. (2013). Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutations. Clinical Genetics, 83(3), 232–237. doi:https://doi.org/10.1111/j.1399-0004.2012.01906.x.PubMedCrossRef

Next-gen Cancer Panels | Ambry Genetics. (n.d.). Retrieved February 4, 2013, from https://doi.org/ambrygen.com/next-gen-cancer-panels

Ng, P. C., Murray, S. S., Levy, S., & Venter, J. C. (2009). An agenda for personalized medicine. Nature, 461(7265), 724–726. doi:https://doi.org/10.1038/461724a.PubMedCrossRef

Nicolaides, N. C., Papadopoulos, N., Liu, B., Wei, Y. F., Carter, K. C., Ruben, S. M., et al. (1994). Mutations of two PMS homologues in hereditary nonpolyposis colon cancer. Nature, 371(6492), 75–80. doi:https://doi.org/10.1038/371075a0.PubMedCrossRef

Ormond, K. E., Wheeler, M. T., Hudgins, L., Klein, T. E., Butte, A. J., Altman, R. B., et al. (2010). Challenges in the clinical application of whole-genome sequencing. The Lancet, 375(9727), 1749–1751. doi:https://doi.org/10.1016/S0140-6736(10)60599-5.CrossRef

OvaNext | Ambry Genetics. (n.d.). Retrieved October 11, 2013, from https://doi.org/www.ambrygen.com/tests/ovanext

Peltomäki, P. (2003). Role of DNA mismatch repair defects in the pathogenesis of human cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 21(6), 1174–1179.CrossRef

Peltomäki, P., & Vasen, H. F. (1997). Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology, 113(4), 1146–1158.PubMedCrossRef

Pennington, K. P., & Swisher, E. M. (2012). Hereditary ovarian cancer: beyond the usual suspects. Gynecologic Oncology, 124(2), 347–353. doi:https://doi.org/10.1016/j.ygyno.2011.12.415.PubMedCrossRef

Pharoah, P., Guilford, P., Caldas, C., & Theinternationalgastriccancer. (2001). Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology, 121(6), 1348–1353. doi:https://doi.org/10.1053/gast.2001.29611.PubMedCrossRef

Pijpe, A., Andrieu, N., Easton, D. F., Kesminiene, A., Cardis, E., Nogues, C., et al. (2012). Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ, 345(sep06 2), e5660–e5660. doi:https://doi.org/10.1136/bmj.e5660.PubMedPubMedCentralCrossRef

Rahman, N., & Scott, R. H. (2007). Cancer genes associated with phenotypes in monoallelic and biallelic mutation carriers: new lessons from old players. Human Molecular Genetics, 16(Spec No 1), R60–R66. doi:https://doi.org/10.1093/hmg/ddm026.PubMedCrossRef

Rennert, G., Lejbkowicz, F., Cohen, I., Pinchev, M., Rennert, H. S., & Barnett-Griness, O. (2012). MutYH mutation carriers have increased breast cancer risk. Cancer, 118(8), 1989–1993. doi:https://doi.org/10.1002/cncr.26506.PubMedCrossRef

Richards, C. S., Bale, S., Bellissimo, D. B., Das, S., Grody, W. W., Hegde, M. R., et al. (2008). ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genetics in Medicine: Official Journal of the American College of Medical Genetics, 10(4), 294–300. doi:https://doi.org/10.1097/GIM.0b013e31816b5cae.CrossRef

Riley, B. D., Culver, J. O., Skrzynia, C., Senter, L. A., Peters, J. A., Costalas, J. W., et al. (2012). Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling, 21(2), 151–161. doi:https://doi.org/10.1007/s10897-011-9462-x.PubMedCrossRef

Rinella, E. S., Shao, Y., Yackowski, L., Pramanik, S., Oratz, R., Schnabel, F., et al. (2013). Genetic variants associated with breast cancer risk for Ashkenazi Jewish women with strong family histories but no identifiable BRCA1/2 mutation. Human Genetics, 132(5), 523–536. doi:https://doi.org/10.1007/s00439-013-1269-4.PubMedPubMedCentralCrossRef

Roberts, J. S., LaRusse, S. A., Katzen, H., Whitehouse, P. J., Barber, M., Post, S. G., et al. (2003). Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. Alzheimer Disease and Associated Disorders, 17(2), 86–93.PubMedCrossRef

Robson, M. E., Storm, C. D., Weitzel, J., Wollins, D. S., & Offit, K. (2010). American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28(5), 893–901. doi:https://doi.org/10.1200/JCO.2009.27.0660.CrossRef

Rubinstein, W. S., O’Neill, S. M., Peters, J. A., Rittmeyer, L. J., & Stadler, M. P. (2002). Mathematical modeling for breast cancer risk assessment. State of the art and role in medicine. Oncology (Williston Park, N.Y.), 16(8), 1082–1094. discussion 1094, 1097–1099.

Rubinstein, W. S., Jiang, H., Dellefave, L., & Rademaker, A. W. (2009). Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue. Genetics in Medicine: Official Journal of the American College of Medical Genetics, 11(9), 629–639. doi:https://doi.org/10.1097/GIM.0b013e3181afd322.CrossRef

Saadatmand, S., Rutgers, E. J. T., Tollenaar, R. A. E. M., Zonderland, H. M., Ausems, M. G. E. M., Keymeulen, K. B. M. I., et al. (2012). Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial. BMC Cancer, 12, 440. doi:https://doi.org/10.1186/1471-2407-12-440.PubMedPubMedCentralCrossRef

Schlich-Bakker, K. J., ten Kroode, H. F. J., & Ausems, M. G. E. M. (2006). A literature review of the psychological impact of genetic testing on breast cancer patients. Patient Education and Counseling, 62(1), 13–20. doi:https://doi.org/10.1016/j.pec.2005.08.012.PubMedCrossRef

Schwartz, R. S., & D’Andrea, A. D. (2010). Susceptibility Pathways in Fanconi’s Anemia and Breast Cancer. New England Journal of Medicine, 362(20), 1909–1919. doi:https://doi.org/10.1056/NEJMra0809889.CrossRef

Seal, S., Thompson, D., Renwick, A., Elliott, A., Kelly, P., Barfoot, R., et al. (2006). Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nature Genetics, 38(11), 1239–1241. doi:https://doi.org/10.1038/ng1902.PubMedCrossRef

Secretary’s Advisory Committee on Genetics, Health, and Society. (2006, February). Coverage and Reimbursement of Genetic Tests and Services.

Senter, L., Clendenning, M., Sotamaa, K., Hampel, H., Green, J., Potter, J. D., et al. (2008). The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology, 135(2), 419–428. doi:https://doi.org/10.1053/j.gastro.2008.04.026.PubMedCrossRef

Shanley, S., Fung, C., Milliken, J., Leary, J., Barnetson, R., Schnitzler, M., et al. (2009). Breast cancer immunohistochemistry can be useful in triage of some HNPCC families. Familial Cancer, 8(3), 251–255. doi:https://doi.org/10.1007/s10689-008-9226-4.PubMedCrossRef

Sherman, K. A., Miller, S. M., Shaw, L.-K., Cavanagh, K., & Sheinfeld Gorin, S. (2013). Psychosocial approaches to participation in BRCA1/2 genetic risk assessment among African American women: a systematic review. Journal of Community Genetics. doi:https://doi.org/10.1007/s12687-013-0164-y.PubMedPubMedCentralCrossRef

Sistemas Genómicos - Working areas - Biomedicine - Medical Genetics Unit - Oncology. (n.d.). Retrieved October 31, 2013, from https://doi.org/www.sistemasgenomicos.com/web_sg/webing/areas-biomedicina-ugm3.php

Stacey, S. N., Sulem, P., Johannsson, O. T., Helgason, A., Gudmundsson, J., Kostic, J. P., et al. (2006). The BARD1 Cys557Ser Variant and Breast Cancer Risk in Iceland. PLoS Medicine, 3(7), e217. doi:https://doi.org/10.1371/journal.pmed.0030217.PubMedPubMedCentralCrossRef

Starink, T. M., van der Veen, J. P., Arwert, F., de Waal, L. P., de Lange, G. G., Gille, J. J., et al. (1986). The Cowden syndrome: a clinical and genetic study in 21 patients. Clinical genetics, 29(3), 222–233.PubMedCrossRef

Starita, L. M., & Parvin, J. D. (2006). Substrates of the BRCA1-dependent ubiquitin ligase. Cancer Biology & Therapy, 5(2), 137–141.CrossRef

Supreme Court Invalidates Patents on Breast and Ovarian Cancer Genes | American Civil Liberties Union. (n.d.). Retrieved October 14, 2013, from https://doi.org/www.aclu.org/womens-rights/supreme-court-invalidates-patents-breast-and-ovarian-cancer-genes

Swan, M. (2010). Multigenic condition risk assessment in direct-to-consumer genomic services. Genetics in Medicine, 12(5), 279–288. doi:https://doi.org/10.1097/GIM.0b013e3181d5f73b.PubMedCrossRef

Swift, M., Morrell, D., Massey, R. B., & Chase, C. L. (1991). Incidence of cancer in 161 families affected by ataxia-telangiectasia. The New England Journal of Medicine, 325(26), 1831–1836. doi:https://doi.org/10.1056/NEJM199112263252602.PubMedCrossRef

Tabor, H. K., Stock, J., Brazg, T., McMillin, M. J., Dent, K. M., Yu, J.–. H., et al. (2012). Informed consent for whole genome sequencing: A qualitative analysis of participant expectations and perceptions of risks, benefits, and harms. American Journal of Medical Genetics Part A, 158A(6), 1310–1319. doi:https://doi.org/10.1002/ajmg.a.35328.PubMedPubMedCentralCrossRef

Tan, M.–. H., Mester, J. L., Ngeow, J., Rybicki, L. A., Orloff, M. S., & Eng, C. (2012). Lifetime cancer risks in individuals with germline PTEN mutations. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 18(2), 400–407. doi:https://doi.org/10.1158/1078-0432.CCR-11-2283.CrossRef

Tavtigian, S. V., Greenblatt, M. S., Goldgar, D. E., & Boffetta, P. (2008). Assessing pathogenicity: overview of results from the IARC Unclassified Genetic Variants Working Group. Human Mutation, 29(11), 1261–1264. doi:https://doi.org/10.1002/humu.20903.PubMedPubMedCentralCrossRef

Thompson, D., Duedal, S., Kirner, J., McGuffog, L., Last, J., Reiman, A., et al. (2005). Cancer risks and mortality in heterozygous ATM mutation carriers. Journal of the National Cancer Institute, 97(11), 813–822. doi:https://doi.org/10.1093/jnci/dji141.PubMedCrossRef

Thorstenson, Y. R., Roxas, A., Kroiss, R., Jenkins, M. A., Yu, K. M., Bachrich, T., et al. (2003). Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Research, 63(12), 3325–3333.PubMed

Trill, M. D., & Holland, J. (1993). Cross-cultural differences in the care of patients with cancer. General Hospital Psychiatry, 15(1), 21–30. doi:https://doi.org/10.1016/0163-8343(93)90087-5.PubMedCrossRef

Tumor Syndromes (n.d.). Retrieved February 25th, 2014, from https://doi.org/www.cegat.de/Tumor-syndromes_l=1_171.html.

Tung, N., & Silver, D. P. (2011). Chek2 DNA damage response pathway and inherited breast cancer risk. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 29(28), 3813–3815. doi:https://doi.org/10.1200/JCO.2011.37.1476.CrossRef

Vasen, H. F., Stormorken, A., Menko, F. H., Nagengast, F. M., Kleibeuker, J. H., Griffioen, G., et al. (2001). MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 19(20), 4074–4080.CrossRef

Vernarelli, J. A., Roberts, J. S., Hiraki, S., Chen, C. A., Cupples, L. A., & Green, R. C. (2010). Effect of Alzheimer disease genetic risk disclosure on dietary supplement use. The American Journal of Clinical Nutrition, 91(5), 1402–1407. doi:https://doi.org/10.3945/ajcn.2009.28981.PubMedPubMedCentralCrossRef

Walsh, T., Lee, M. K., Casadei, S., Thornton, A. M., Stray, S. M., Pennil, C., et al. (2010). Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America, 107(28), 12629–12633. doi:https://doi.org/10.1073/pnas.1007983107.PubMedPubMedCentralCrossRef

Wang, Y., Cortez, D., Yazdi, P., Neff, N., Elledge, S. J., & Qin, J. (2000). BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes & Development, 14(8), 927–939.

Weischer, M., Bojesen, S. E., Ellervik, C., Tybjaerg-Hansen, A., & Nordestgaard, B. G. (2008). CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 26(4), 542–548. doi:https://doi.org/10.1200/JCO.2007.12.5922.CrossRef

White, M., & Dorman, S. (2000). Confronting Information Overload. Journal of School Health, 70(4), 160–161.CrossRef

Williams, C., Brunskill, S., Altman, D., Briggs, A., Campbell, H., Clarke, M., et al. (2006). Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health Technology Assessment (Winchester, England), 10(34), iii–iv. ix–xi, 1–204.

Wu, X., Platt, J. L., & Cascalho, M. (2003). Dimerization of MLH1 and PMS2 Limits Nuclear Localization of MutL. Molecular and Cellular Biology, 23(9), 3320–3328. doi:https://doi.org/10.1128/MCB.23.9.3320-3328.2003.PubMedPubMedCentralCrossRef

Yasmeen, S., Hubbard, R. A., Romano, P. S., Zhu, W., Geller, B. M., Onega, T., et al. (2012). Risk of advanced-stage breast cancer among older women with comorbidities. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 21(9), 1510–1519. doi:https://doi.org/10.1158/1055-9965.EPI-12-0320.CrossRef

Zick, C. D., Mathews, C. J., Roberts, J. S., Cook-Deegan, R., Pokorski, R. J., & Green, R. C. (2005). Genetic testing for Alzheimer’s disease and its impact on insurance purchasing behavior. Health Affairs (Project Hope), 24(2), 483–490. doi:https://doi.org/10.1377/hlthaff.24.2.483.CrossRef

Titel: Cancer Risk Assessment Using Genetic Panel Testing: Considerations for Clinical Application
verfasst von: Susan Hiraki
Erica S. Rinella
Freya Schnabel
Ruth Oratz
Harry Ostrer
Publikationsdatum: 01.08.2014
Verlag: Springer US
Erschienen in: Journal of Genetic Counseling / Ausgabe 4/2014
Print ISSN: 1059-7700
Elektronische ISSN: 1573-3599
DOI: https://doi.org/10.1007/s10897-014-9695-6

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Welche Übungen helfen gegen Diastase recti abdominis?

30.04.2024 Schwangerenvorsorge Nachrichten

Die Autorinnen und Autoren einer aktuellen Studie aus Griechenland sind sich einig, dass Bewegungstherapie, einschließlich Übungen zur Stärkung der Bauchmuskulatur und zur Stabilisierung des Rumpfes, eine Diastase recti abdominis postpartum wirksam reduzieren kann. Doch vieles ist noch nicht eindeutig belegt.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Genetic Counseling Practice in Next Generation Sequencing Research: Implications for the Ethical Oversight of the Informed Consent Process

Points to Consider in the Clinical Use of NGS Panels for Mitochondrial Disease: An Analysis of Gene Inclusion and Consent Forms

The Evolution of Cancer Risk Assessment in the Era of Next Generation Sequencing

Genetic Testing of Children for Predisposition to Mood Disorders: Anticipating the Clinical Issues